Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 1;55(Suppl 1):i26-i30.
doi: 10.1093/ejcts/ezy410.

The role of transcatheter mitral valve therapy in heart failure

Hendrik Treede  1 , Efstratios I Charitos  1
Affiliations
Review

The role of transcatheter mitral valve therapy in heart failure

Hendrik Treede et al. Eur J Cardiothorac Surg. .

Abstract

Mitral valve regurgitation is detected in up to 75% of patients with heart failure. Interventional mitral valve therapies can be used to treat mitral regurgitation with very low morbidity and mortality rates and minimal invasiveness. Devices intended for the replacement of the mitral valve still require significant development and refinement before entering clinical practice on a large scale. The derived benefit of these therapies, the priority (repair over replacement) and the therapeutic role in patients with secondary mitral regurgitation due to heart failure remain to be investigated.

Keywords: Heart failure; Mitral interventions; Mitral valve regurgitation.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Transcatheter mitral valve replacement devices. Top line from left to right: the CardiAQ™ valve (Edwards Lifesciences, Irvine, CA, USA), the Tiara™ valve (Neovasc Inc., Richmond, BC, Canada) and the Tendyne™ valve (Abbott Vascular, Santa Clara, CA, USA). Bottom line from left to right: the Intrepid™ valve (Medtronic, Minneapolis, MN, USA), the High Life™ valve (High Life, Paris, France) and the Caisson™ valve (LivaNova, Milan, Italy).
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Guha K, McDonagh T.. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013;9:123–7. - PMC - PubMed
    1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7–11. - PMC - PubMed
    1. Benjamin MM, Smith RL, Grayburn PA.. Ischemic and functional mitral regurgitation in heart failure: natural history and treatment. Curr Cardiol Rep 2014;16:517.. - PubMed
    1. Trichon BH, Felker GM, Shaw LK, Cabell CH, O'Connor CM.. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003;91:538–43. - PubMed
    1. Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S.. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 2011;97:1675–80. - PubMed